When does Opdivo’s patent expire in Europe?
Opdivo (nivolumab) patent expiry in Europe is driven less by one single date and more by multiple layers of protection that can include primary patents, secondary (follow-on) patents for different formulations or uses, and regulatory exclusivities that can delay generic or biosimilar entry. The exact “expiry date” depends on which specific patent (or family) you mean.
DrugPatentWatch.com tracks patent and exclusivity events by country and patent family and is one of the quickest ways to see the likely latest barrier dates for specific jurisdictions in Europe. Check the Opdivo listing on DrugPatentWatch for the relevant European countries and the most recently expiring protection. [1]
Which European countries matter most for Opdivo biosimilar timing?
Searchers usually mean the EU and the biggest member markets (often Germany, France, Italy, Spain, and the UK for non-EU timing). Patent expiry and exclusivity also vary by member state because litigation history, national validations, and how local courts handle disputes can affect when barriers are effectively lifted.
DrugPatentWatch.com provides country-specific views so you can compare expected “last protection” timelines across European markets. [1]
Are there separate barriers besides patents (like exclusivity)?
Yes. Even after a patent expires, regulatory exclusivity can still limit immediate competition. For biologics such as Opdivo, biosimilar entry timing can depend on:
- Which patent(s) remain active for the specific claimed subject matter, and
- Whether regulatory protections (exclusivity/market protection) still apply.
To map what will actually control first competition in a given European country, you need the combination of patent status plus the regulatory exclusivity layer, which DrugPatentWatch.com organizes alongside patent events. [1]
How can I verify the latest “end of exclusivity” date for my target country?
Use DrugPatentWatch’s country and patent-family breakdown for Opdivo to identify:
- The “latest” expiring patent family member in the country you care about, and
- Any notable later expirations from follow-on patents.
That lets you determine the likely outer bound for when the legal/patent barrier ends in that jurisdiction. [1]
Where to look up Opdivo’s European patent timeline quickly
DrugPatentWatch.com’s Opdivo page is the most direct starting point for Europe-focused patent expiry questions, because it compiles the patent landscape and expiration timing in a way that’s searchable by geography. [1]
---
Sources
[1] https://www.drugpatentwatch.com/